Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature
© Sabatier et al; licensee BioMed Central Ltd. 2010
Received: 21 May 2010
Accepted: 24 November 2010
Published: 24 November 2010
Low-grade extraskeletal osteosarcomas (ESOS) are extremely rare.
We present the first case of low-grade ESOS of the chest wall, which occurred in a 30-year-old man. Because of initial misdiagnosis and patient's refusal of surgery, the diagnosis was done after a 4-year history of a slowly growing mass in soft tissues, leading to a huge (30-cm diameter) calcified mass locally extended over the left chest wall. Final diagnosis was helped by molecular analysis of MDM2 and CDK4 oncogenes. Unfortunately, at this time, no surgical treatment was possible due to loco-regional extension, and despite chemotherapy, the patient died one year after diagnosis, five years after the first symptoms.
We describe the clinical, radiological and bio-pathological features of this unique case, and review the literature concerning low-grade ESOS. Our case highlights the diagnostic difficulties for such very rare tumours and the interest of molecular analysis in ambiguous cases.
Osteosarcoma (OS) typically develops in the intramedullary cavity of long bones of adolescents and young adults and is a high-grade tumour [1, 2]. Extraskeletal osteosarcoma (ESOS) is a very rare form of OS (~5%) located in the soft tissues without connection to the skeleton. Its usual aspect is that of a large and deep high-grade bone-forming sarcoma, developed in the limbs of patients older than 40 years [2, 3], with a very aggressive behaviour .
Low-grade ESOS, whose histology is similar to well-differentiated intraosseous and parosteal OS, is extremely rare. To date only six cases have been reported in the literature. Here, we describe a new case of low-grade ESOS, which developed in the chest wall. Initial diagnosis, based on radiological and histological aspects, was erroneously myositis ossificans. Correct final diagnosis, suspected by the clinical evolution, was confirmed by molecular analysis, but was too late, and the patient died from extensive loco-regional progression. We hope that this case report underlines the diagnostic difficulties of this tumour, and the interest of molecular analysis in ambiguous cases.
The patient was a 30-year-old man, Caucasian type, without any specific medical personal or familial history. He was referred to our institution in November 2006 for diagnosis and treatment of a huge tumour of the left chest wall, detected for the first time 4 years earlier. Indeed, in May 2002, he presented a 3-cm painless, mobile, intramuscular mass on the left shoulder near scapula, three months after a benign trauma on this region. Magnetic resonance imaging (MRI) showed elements in favour of a myositis ossificans circumscripta. Percutaneous biopsy showed areas of osteogenesis with mature bone trabeculae in muscle. The intertrabecular space revealed benign-appearing fibroblastic proliferation. The retained diagnosis was myositis ossificans. The benignity of this disease with usual spontaneous stabilisation or regression , and the lack of functional impact of the lesion led the physicians to decide observation.
Unfortunately at this time, more than 4 years after the first symptoms, curative surgical resection was not possible because of to the loco-regional extension. We delivered chemotherapy with an API/AI sequential regimen, which combined adriamycin (A), cisplatinum (P) and ifosfamide (I). The disease was stable after 2 API/AI cycles. After 4 additional API cycles, the disease progressed with extension of cutaneous nodules and tumour mass associated to the apparition of left pleuritis. The ECOG status was 3, and the patient complained of thoracic pain and dyspnoea. Palliative radiation therapy was not possible technically due to the tumour volume. A thoracoscopic talcage was done, followed by trabectedin-based chemotherapy. Three weeks after the first cycle, the patient deteriorated rapidly and died of respiratory failure secondary to loco-regional extension, 5 years after the initial symptoms.
Low-grade ESOS are extremely rare with only 6 cases reported to date in the English literature since 1953 [10–14]. To our knowledge, the present case is the seventh case reported, and the first one developed in the chest wall.
Seven cases of low-grade ESOS reported in literature.
Lung metastases, 4 years, death
Right popliteal fossa
Lost to follow-up,
S + CT
Lung and retroperitoneum metastases, 4 years, death
death 5 years after first symptoms and 1 year after diagnosis
However, differential diagnosis may be problematic at early stages with other ossified lesions of soft tissues: benign lesions such as myositis ossificans circumscripta (MOC), ossifying lipoma, soft tissue osteoma or chondroma, and ossifying fibromyxoid tumour, as well as malignant lesions such as classical high-grade ESOS, parosteal OS, mesenchymal chondrosarcoma, and synovial sarcoma. MOC is a benign heterotopic ossification of soft tissues characteristically associated with direct trauma . It is one of the most important differential diagnoses, which was initially evoked - based on radiological and/or pathological aspects - in at least 3 out of the 7 reported cases of low-grade ESOS. Furthermore, a number of cases of ESOS presumably arising from MOC have been reported [16–19]. In MOC, both mature and immature bone is seen, as well as a prominent spindle cell and chondroid component, with a specific architecture described as the "zonal phenomenon". This phenomenon refers to the presence of a clearly benign, reactive rim of mature bone at the periphery, which encompasses a central area of fusiform cells and immature bone interlaced with osteoid and chondroid. In our patient, several initial aspects led physicians to erroneously propose this diagnosis: i) the initial traumatism a few weeks before the discovery of the tumour, ii) the first MRI observation which showed an extraosseous mass with a mature calcification peripherally predominant, iii) and the pathological aspects of mature lamellar bone synthesis by non atypical cells without abnormal mitoses. However, the radiological modifications observed later with the development of a centrifuge ossification corresponding to microscopic features to a reverse pattern of ossification ("reverse zonal phenomenon"), and of course, the progressive tumour growth and extension were that of a malignant tumour. Due to the initial misdiagnosis followed by the absence of follow-up, and the patient's refusal of surgery, the correct diagnosis was done too late and evolution was fatal.
Today, molecular analyses may resolve the diagnostic dilemma between low-grade ESOS and benign lesions. Amplification of genes in the 12q13-15 region, such as SAS, CDK4 and MDM2, is relatively frequent in osteosarcoma, notably in low-grade parosteal OS, making them suitable as markers for distinguishing them from benign ossifying [6–9]. In our patient, IHC and FISH analyses for MDM2 and CDK4 were done on 2006 from paraffin-embedded tumour samples biopsied on 2004. They showed the overexpression and amplification of these two oncogenes, thus ruling out the diagnosis of myositis ossificans and confirming that of sarcoma. To our knowledge, it is the first case of low-grade ESOS with documented molecular alterations.
Our case is the seventh case of low-grade ESOS reported in literature, and the first case located in the chest wall. It highlights the importance and difficulty of early diagnosis of this very rare tumour, which may be confused with numerous benign diseases, notably myositis ossificans. Misdiagnosis may be fatal, as surgery is the only curative approach for these patients. In this context, it is worth noting the importance of molecular analysis (amplification and/or ovexpression of MDM2 and CDK4) to help diagnosis in ambiguous cases.
Written informed consent was obtained from the patient's relatives for publication of this case report and any accompanying images.
- Huvos AG: Bone tumors. Diagnosis, treatment and prognosis. 1991, Philadelphia: WB Saunders, 2
- Bane BL, Evans HL, Ro JY: Extraskeletal osteosarcoma: a clinicopathologic review of 26 cases. Cancer. 1990, 66: 2762-2770. 10.1002/1097-0142(19900615)65:12<2762::AID-CNCR2820651226>3.0.CO;2-K.View Article
- Chung EB, Enzinger FM: Extraskeletal osteosarcoma. Cancer. 1987, 60: 1132-1142. 10.1002/1097-0142(19870901)60:5<1132::AID-CNCR2820600536>3.0.CO;2-L.View ArticlePubMed
- Enzinger FM, Weiss SW: Soft tissue sarcomas. 1995, St Louis: Mosby-Year Book
- Bernard M, Coumbaras M, Zeitoun F, Arrivé L, Tubiana JM, Le Hir P: Radiological spectrum of myositis ossificans circumscripta evolution. J Radiol. 2003, 84 (1): 54-56.PubMed
- Gamberi G, Ragazzini P, Benassi MS, Ferrari C, Sollazzo MR, Molendini L, Merli M, Magagnoli G, Ruggieri P, Balladelli A, Orlando C, Bacchini P, Pazzagli M, Picci P: Analysis of 12q13-15 genes in parosteal osteosarcoma. Clinical Orthopaedics Related Research. 2000, 195-204. 10.1097/00003086-200008000-00026. 377
- Gisselsson D, Pålsson E, Höglund M, Domanski H, Mertens F, Pandis N, Sciot R, Dal Cin P, Bridge JA, Mandahl N: Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer. 2002, 33 (2): 133-140. 10.1002/gcc.1219.View ArticlePubMed
- Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL: Co-amplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene. 1999, 18: 783-788. 10.1038/sj.onc.1202346.View ArticlePubMed
- Ragland BD, Bell WC, Lopez RR, Siegal GP: Cytogenetics and molecular biology of osteosarcoma. Laboratory Investigation. 2002, 82: 365-373.View ArticlePubMed
- Umiker W, Jaffe HL: Ossifying fibrosarcoma (extraskeletal osteogenic sarcoma) of thigh muscle; report of a case with recurrence and widespread metastases more than four and a half years after excision. Annals of Surgery. 1953, 138 (5): 795-800. 10.1097/00000658-195311000-00019.PubMed CentralView ArticlePubMed
- Present D, Bertoni F, Laus M, Bacchini P, Bocanera M: Case report 565: Low-grade osteosarcoma of soft tissues (popliteal fossa). Skeletal Radiology. 1989, 18 (6): 471-474. 10.1007/BF00368619.View ArticlePubMed
- Yi ES, Shmookler BM, Malawer MM, Sweet DE: Well-differentiated extraskeletal osteosarcoma. A soft-tissue homologue of parosteal osteosarcoma. Archives of Pathology and Laboratory Medicine. 1991, 115 (9): 906-909.PubMed
- Okada K, Ito H, Miyakoshi N, Sageshima M, Nishida J, Itoi E: A low-grade extraskeletal osteosarcoma. Skeletal Radiology. 2003, 32 (3): 165-169. 10.1007/s00256-002-0589-6.View ArticlePubMed
- Abramovici LC, Hytiroglou P, Klein RM, Karkavelas G, Drevelegas A, Panousi E, Steiner GC: Well-differentiated extraskeletal osteosarcoma: report of 2 cases, 1 with dedifferentiation. Human Pathology. 2005, 36 (4): 439-443. 10.1016/j.humpath.2005.01.023.View ArticlePubMed
- Ogilvie-Harris DJ, Fornasier VL: Pseudomalignant myositis ossificans: heterotopic new-bone formation without a history of trauma. Journal of Bone and Joint Surgery American volume. 1980, 62: 1274-1283.
- Konishi E, Kusuzaki K, Murata H, Tsuchihashi Y, Beabout JW, Unni KK: Extraskeletal osteosarcoma arising in myositis ossificans. Skeletal Radiology. 2001, 30: 39-43. 10.1007/s002560000298.View ArticlePubMed
- Huvos AG, Heilweil M, Bretsky SS: The pathology of malignant fibrous histiocytoma of bone. A study of 130 patients. American Journal of Surgical Pathology. 1985, 9: 853-871. 10.1097/00000478-198512000-00002.View ArticlePubMed
- Shanoff LB, Spira M, Hardy SB: Myositis ossificans: evolution to osteogenic sarcoma. Report of a histologically verified case. American Journal of Surgery. 1967, 113: 537-541. 10.1016/0002-9610(67)90203-6.View ArticlePubMed
- Järvi OH, Kvist HT, Vainio PV: Extraskeletal retroperitoneal osteosarcoma probably arising from myositis ossificans. Acta Pathologica Microbiology Scandinavia. 1968, 74: 11-25. 10.1111/j.1699-0463.1968.tb03450.x.View Article
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/645/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.